Codiak BioSciences, Inc. Common Stock
CDAK
CDAK was delisted on the 4th of April, 2023.
47 hedge funds and large institutions have $310M invested in Codiak BioSciences, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 47 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$37.2M |
| 2 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$34.5M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$10.8M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$7.97M |
| 5 |
DM
Deerfield Management
New York
|
+$5.95M |
Top Sellers
CDAK Hedge Fund Activity: Q4 2020 in Review
47 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Codiak BioSciences, Inc. Common Stock (CDAK) for Q4 2020, worth a combined $310M.
Buyers outnumbered sellers: 47 funds opened new CDAK positions and 0 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $37.2M.
- 47 institutional investors held Codiak BioSciences, Inc. Common Stock (CDAK) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $310M of Codiak BioSciences, Inc. Common Stock stock for Q4 2020.
- 47 funds opened new Codiak BioSciences, Inc. Common Stock positions in Q4 2020 and 0 closed out, a net change of +47 holders.
- The largest Codiak BioSciences, Inc. Common Stock buyer in Q4 2020 was Fidelity Investments, an estimated $37.2M added.
Based on aggregated 13F filings for Q4 2020.